Literature DB >> 32160292

Coding and noncoding drivers of mantle cell lymphoma identified through exome and genome sequencing.

Prasath Pararajalingam1, Krysta M Coyle1, Sarah E Arthur1, Nicole Thomas1, Miguel Alcaide1, Barbara Meissner2,3, Merrill Boyle2,3, Quratulain Qureshi1, Bruno M Grande1, Christopher Rushton1, Graham W Slack2,3, Andrew J Mungall4, Constantine S Tam5,6, Rishu Agarwal5, Sarah-Jane Dawson5,6, Georg Lenz7, Sriram Balasubramanian8, Randy D Gascoyne2,3, Christian Steidl2,3, Joseph Connors2,3, Diego Villa2,3, Timothy E Audas1, Marco A Marra2,3, Nathalie A Johnson9, David W Scott2,3, Ryan D Morin1,4.   

Abstract

Mantle cell lymphoma (MCL) is an uncommon B-cell non-Hodgkin lymphoma (NHL) that is incurable with standard therapies. The genetic drivers of this cancer have not been firmly established, and the features that contribute to differences in clinical course remain limited. To extend our understanding of the biological pathways involved in this malignancy, we performed a large-scale genomic analysis of MCL using data from 51 exomes and 34 genomes alongside previously published exome cohorts. To confirm our findings, we resequenced the genes identified in the exome cohort in 191 MCL tumors, each having clinical follow-up data. We confirmed the prognostic association of TP53 and NOTCH1 mutations. Our sequencing revealed novel recurrent noncoding mutations surrounding a single exon of the HNRNPH1gene. In RNA-seq data from 103 of these cases, MCL tumors with these mutations had a distinct imbalance of HNRNPH1 isoforms. This altered splicing of HNRNPH1 was associated with inferior outcomes in MCL and showed a significant increase in protein expression by immunohistochemistry. We describe a functional role for these recurrent noncoding mutations in disrupting an autoregulatory feedback mechanism, thereby deregulating HNRNPH1 protein expression. Taken together, these data strongly imply a role for aberrant regulation of messenger RNA processing in MCL pathobiology.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32160292      PMCID: PMC7440974          DOI: 10.1182/blood.2019002385

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  74 in total

1.  A Pleiotropic RNA-Binding Protein Controls Distinct Cell Cycle Checkpoints to Drive Resistance of p53-Defective Tumors to Chemotherapy.

Authors:  Karl A Merrick; Sandra Morandell; Chang-Qi Zhu; Ian G Cannell; Christian J Braun; Robert A Grant; Eleanor R Cameron; Ming-Sound Tsao; Michael T Hemann; Michael B Yaffe
Journal:  Cancer Cell       Date:  2015-11-09       Impact factor: 31.743

2.  High-throughput analyses of hnRNP H1 dissects its multi-functional aspect.

Authors:  Philip J Uren; Emad Bahrami-Samani; Patricia Rosa de Araujo; Christine Vogel; Mei Qiao; Suzanne C Burns; Andrew D Smith; Luiz O F Penalva
Journal:  RNA Biol       Date:  2016-01-13       Impact factor: 4.652

Review 3.  Mantle Cell Lymphoma.

Authors:  Chan Yoon Cheah; John F Seymour; Michael L Wang
Journal:  J Clin Oncol       Date:  2016-01-11       Impact factor: 44.544

4.  A novel nucleocytoplasmic shuttling sequence of DAZAP1, a testis-abundant RNA-binding protein.

Authors:  Yi-Tzu Lin; Pauline H Yen
Journal:  RNA       Date:  2006-06-13       Impact factor: 4.942

5.  Heterogeneous nuclear ribonucleoprotein H blocks MST2-mediated apoptosis in cancer cells by regulating A-Raf transcription.

Authors:  Jens Rauch; Eric O'Neill; Brigitte Mack; Christoph Matthias; Markus Munz; Walter Kolch; Olivier Gires
Journal:  Cancer Res       Date:  2010-02-09       Impact factor: 12.701

6.  SF3B1 and other novel cancer genes in chronic lymphocytic leukemia.

Authors:  Lili Wang; Michael S Lawrence; Youzhong Wan; Petar Stojanov; Carrie Sougnez; Kristen Stevenson; Lillian Werner; Andrey Sivachenko; David S DeLuca; Li Zhang; Wandi Zhang; Alexander R Vartanov; Stacey M Fernandes; Natalie R Goldstein; Eric G Folco; Kristian Cibulskis; Bethany Tesar; Quinlan L Sievers; Erica Shefler; Stacey Gabriel; Nir Hacohen; Robin Reed; Matthew Meyerson; Todd R Golub; Eric S Lander; Donna Neuberg; Jennifer R Brown; Gad Getz; Catherine J Wu
Journal:  N Engl J Med       Date:  2011-12-12       Impact factor: 91.245

7.  Frequent NFKBIE deletions are associated with poor outcome in primary mediastinal B-cell lymphoma.

Authors:  Larry Mansouri; Daniel Noerenberg; Emma Young; Elena Mylonas; Maysaa Abdulla; Mareike Frick; Fazila Asmar; Viktor Ljungström; Markus Schneider; Kenichi Yoshida; Aron Skaftason; Tatjana Pandzic; Blanca Gonzalez; Anna Tasidou; Nils Waldhueter; Alfredo Rivas-Delgado; Maria Angelopoulou; Marita Ziepert; Christopher Maximilian Arends; Lucile Couronné; Dido Lenze; Claudia D Baldus; Christian Bastard; Jessica Okosun; Jude Fitzgibbon; Bernd Dörken; Hans G Drexler; Damien Roos-Weil; Clemens A Schmitt; Helga D Munch-Petersen; Thorsten Zenz; Martin-Leo Hansmann; Jonathan C Strefford; Gunilla Enblad; Olivier A Bernard; Elisabeth Ralfkiaer; Martin Erlanson; Penelope Korkolopoulou; Magnus Hultdin; Theodora Papadaki; Kirsten Grønbæk; Armando Lopez-Guillermo; Seishi Ogawa; Ralf Küppers; Kostas Stamatopoulos; Niki Stavroyianni; George Kanellis; Andreas Rosenwald; Elias Campo; Rose-Marie Amini; German Ott; Theodoros P Vassilakopoulos; Michael Hummel; Richard Rosenquist; Frederik Damm
Journal:  Blood       Date:  2016-09-26       Impact factor: 22.113

8.  Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs.

Authors:  Christopher T Saunders; Wendy S W Wong; Sajani Swamy; Jennifer Becq; Lisa J Murray; R Keira Cheetham
Journal:  Bioinformatics       Date:  2012-05-10       Impact factor: 6.937

9.  Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.

Authors:  Rishu Agarwal; Yih-Chih Chan; Constantine S Tam; Tane Hunter; Dane Vassiliadis; Charis E Teh; Rachel Thijssen; Paul Yeh; Stephen Q Wong; Sarah Ftouni; Enid Y N Lam; Mary Ann Anderson; Christiane Pott; Omer Gilan; Charles C Bell; Kathy Knezevic; Piers Blombery; Kathleen Rayeroux; Adrian Zordan; Jason Li; David C S Huang; Meaghan Wall; John F Seymour; Daniel H D Gray; Andrew W Roberts; Mark A Dawson; Sarah-Jane Dawson
Journal:  Nat Med       Date:  2018-11-19       Impact factor: 53.440

10.  Mutational heterogeneity in cancer and the search for new cancer-associated genes.

Authors:  Michael S Lawrence; Petar Stojanov; Paz Polak; Gregory V Kryukov; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Chip Stewart; Craig H Mermel; Steven A Roberts; Adam Kiezun; Peter S Hammerman; Aaron McKenna; Yotam Drier; Lihua Zou; Alex H Ramos; Trevor J Pugh; Nicolas Stransky; Elena Helman; Jaegil Kim; Carrie Sougnez; Lauren Ambrogio; Elizabeth Nickerson; Erica Shefler; Maria L Cortés; Daniel Auclair; Gordon Saksena; Douglas Voet; Michael Noble; Daniel DiCara; Pei Lin; Lee Lichtenstein; David I Heiman; Timothy Fennell; Marcin Imielinski; Bryan Hernandez; Eran Hodis; Sylvan Baca; Austin M Dulak; Jens Lohr; Dan-Avi Landau; Catherine J Wu; Jorge Melendez-Zajgla; Alfredo Hidalgo-Miranda; Amnon Koren; Steven A McCarroll; Jaume Mora; Brian Crompton; Robert Onofrio; Melissa Parkin; Wendy Winckler; Kristin Ardlie; Stacey B Gabriel; Charles W M Roberts; Jaclyn A Biegel; Kimberly Stegmaier; Adam J Bass; Levi A Garraway; Matthew Meyerson; Todd R Golub; Dmitry A Gordenin; Shamil Sunyaev; Eric S Lander; Gad Getz
Journal:  Nature       Date:  2013-06-16       Impact factor: 49.962

View more
  12 in total

1.  EZH2 expression is associated with inferior overall survival in mantle cell lymphoma.

Authors:  Diana Martinez-Baquero; Ali Sakhdari; Huan Mo; Do Hwan Kim; Rashmi Kanagal-Shamanna; Shaoying Li; Ken H Young; Dennis P O'Malley; Ahmet Dogan; Preetesh Jain; Michael L Wang; Timothy J McDonnell; Roberto N Miranda; Francisco Vega; L Jeffrey Medeiros; Chi Young Ok
Journal:  Mod Pathol       Date:  2021-08-10       Impact factor: 7.842

2.  Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial.

Authors:  Ryan D Morin; David W Scott; Georg Lenz; Ciara L Freeman; Prasath Pararajalingam; Ling Jin; Sriram Balasubramanian; Aixiang Jiang; Wendan Xu; Michael Grau; Myroslav Zapukhlyak; Merrill Boyle; Brendan Hodkinson; Michael Schaffer; Christopher Enny; Sanjay Deshpande; Steven Sun; Jessica Vermeulen
Journal:  Leukemia       Date:  2022-08-13       Impact factor: 12.883

3.  HNRNPH1 destabilizes the G-quadruplex structures formed by G-rich RNA sequences that regulate the alternative splicing of an oncogenic fusion transcript.

Authors:  Tam Vo; Tayvia Brownmiller; Katherine Hall; Tamara L Jones; Sulbha Choudhari; Ioannis Grammatikakis; Katelyn R Ludwig; Natasha J Caplen
Journal:  Nucleic Acids Res       Date:  2022-06-24       Impact factor: 19.160

4.  Early relapse identifies MCL patients with inferior survival after intensive or less intensive frontline therapy.

Authors:  David A Bond; Jeffrey M Switchenko; Diego Villa; Kami Maddocks; Michael Churnetski; Alina S Gerrie; Subir Goyal; Krithika Shanmugasundaram; Oscar Calzada; Bhaskar Kolla; Veronika Bachanova; James N Gerson; Stefan K Barta; Brian T Hill; Yazeed Sawalha; Peter Martin; Edward Maldonado; Max Gordon; Alexey V Danilov; Natalie S Grover; Stephanie Mathews; Madelyn Burkart; Reem Karmali; Nilanjan Ghosh; Steven I Park; Narendranath Epperla; Talha Badar; Jin Guo; Mehdi Hamadani; Timothy S Fenske; Mary-Kate Malecek; Brad S Kahl; Christopher R Flowers; Kristie A Blum; Jonathon B Cohen
Journal:  Blood Adv       Date:  2021-12-14

5.  Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis.

Authors:  Holly A Hill; Xinyue Qi; Preetesh Jain; Krystle Nomie; Yucai Wang; Shouhao Zhou; Michael L Wang
Journal:  Blood Adv       Date:  2020-07-14

6.  Etodolac improves collagen induced rheumatoid arthritis in rats by inhibiting synovial inflammation, fibrosis and hyperplasia.

Authors:  Qin Feng; Wenkai Xia; Shenglan Wang; Guoxin Dai; Weimei Jiao; Na Guo; Honghua Li; Guimin Zhang
Journal:  Mol Biomed       Date:  2021-10-25

7.  Genomic and transcriptomic profiling reveals distinct molecular subsets associated with outcomes in mantle cell lymphoma.

Authors:  Shuhua Yi; Yuting Yan; Meiling Jin; Supriyo Bhattacharya; Yi Wang; Yiming Wu; Lu Yang; Eva Gine; Guillem Clot; Lu Chen; Ying Yu; Dehui Zou; Jun Wang; An T Phan; Rui Cui; Fei Li; Qi Sun; Qiongli Zhai; Tingyu Wang; Zhen Yu; Lanting Liu; Wei Liu; Rui Lyv; Weiwei Sui; Wenyang Huang; Wenjie Xiong; Huijun Wang; Chengwen Li; Zhijian Xiao; Mu Hao; Jianxiang Wang; Tao Cheng; Silvia Bea; Alex F Herrera; Alexey Danilov; Elias Campo; Vu N Ngo; Lugui Qiu; Lili Wang
Journal:  J Clin Invest       Date:  2022-02-01       Impact factor: 19.456

8.  Prognostic Value of Heterogeneity Index Derived from Baseline 18F-FDG PET/CT in Mantle Cell Lymphoma.

Authors:  Fei Liu; Bingxin Gu; Nan Li; Herong Pan; Wen Chen; Ying Qiao; Shaoli Song; Xiaosheng Liu
Journal:  Front Oncol       Date:  2022-04-14       Impact factor: 5.738

9.  Expression patterns and prognostic potential of circular RNAs in mantle cell lymphoma: a study of younger patients from the MCL2 and MCL3 clinical trials.

Authors:  Lasse S Kristensen; Kirsten Grønbæk; Mette Dahl; Simon Husby; Christian W Eskelund; Søren Besenbacher; Søren Fjelstrup; Christophe Côme; Sara Ek; Arne Kolstad; Riikka Räty; Mats Jerkeman; Christian H Geisler; Jørgen Kjems
Journal:  Leukemia       Date:  2021-07-09       Impact factor: 11.528

10.  Clinical Features and Prognostic Significance of NOTCH1 Mutations in Diffuse Large B-Cell Lymphoma.

Authors:  Zhongqi Li; Fang Yu; Wenle Ye; Liping Mao; Jiansong Huang; Yang Shao; Junrong Yan; Wenjuan Yu; Jie Jin; Jinghan Wang
Journal:  Front Oncol       Date:  2021-12-09       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.